048410 — Hyundai Bioscience Co Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesHighly SpeculativeSmall CapSucker Stock

Annual income statement for Hyundai Bioscience Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	12,511	9,241	7,852	9,481	15,050
Cost of Revenue
Gross Profit	6,563	3,521	2,683	5,041	11,865
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	19,880	26,529	25,840	24,035	14,259
Operating Profit	-7,369	-17,287	-17,989	-14,554	791
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-7,933	-19,808	-16,613	-14,498	-6,930
Provision for Income Taxes
Net Income After Taxes	-8,260	-20,051	-15,807	-14,499	-6,930
Net Income Before Extraordinary Items
Net Income	-8,260	-20,051	-15,807	-14,499	-6,930
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-8,260	-20,051	-15,807	-14,499	-6,930
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-84.2	-194	-254	-135	-81.9
Dividends per Share